RecruitingNCT06413433
Solriamfetol or placebo for binge eating
About this title
Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol
Read the official source — NCT06413433Medication studyAges 18–55United StatesEating disorders
Understand this study
Who could participate?
Listed age limits: 18 years to 55 years.
- Listed locations
- Encino and 44 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: April 26, 2024
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 450
- Sponsor
- Axsome Therapeutics, Inc.
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT06413433
- Official title
Show the full official title
A Phase 3, Randomized, Double-blind, Placebo-Controlled Trial of Solriamfetol in Adults With Binge Eating Disorder (BED)
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Encino · Garden Grove · Long Beach
38 more locations
- Mission Viejo
- San Diego
- Santa Ana
- Walnut Creek
- West Covina
- Colorado Springs
- Cromwell
- Clermont
- Fort Myers
- Jacksonville
- Lauderhill
- Miami
- Miami Lakes
- Orlando
- Marietta
- Overland Park
- Boston
- Methuen
- Saint Charles
- Cherry Hill
- Princeton
- Mount Kisco
- New York
- Raleigh
- Cincinnati
- Mason
- Middleburg Heights
- North Canton
- Portland
- Allentown
- Media
- Greenville
- North Charleston
- Memphis
- Austin
- Dallas
- San Antonio
- Draper
Questions about this study
Who is behind this study?
The study sponsor is Axsome Therapeutics, Inc.
Does this study involve medication?
Yes. The study involves medication, including Solriamfetol 150 mg, Solriamfetol 300 mg and Placebo.
Who can participate?
Listed age limits: 18 years to 55 years.
Is this study still recruiting?
The registry lists this study as recruiting.
